Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124642
Filing Date
2024-11-12
Accepted
2024-11-12 08:17:47
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001991792-20240930.htm   iXBRL 10-Q 1801440
2 EX-31.1 ck0001991792-ex31_1.htm EX-31.1 15018
3 EX-31.2 ck0001991792-ex31_2.htm EX-31.2 14824
4 EX-32.1 ck0001991792-ex32_1.htm EX-32.1 9062
5 EX-32.2 ck0001991792-ex32_2.htm EX-32.2 9137
  Complete submission text file 0000950170-24-124642.txt   6653151

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20240930.xsd EX-101.SCH 958286
67 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20240930_htm.xml XML 973437
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 241443657
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)